RYPLAZIM- plasminogen injection, powder, lyophilized, for solution
Prometic Biotherapeutics, Inc.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use RYPLAZIM® safely and effectively. See full prescribing information for RYPLAZIM.
RYPLAZIM® (plasminogen, human-tvmh) lyophilized powder for reconstitution, for intravenous use Initial U.S. Approval: 2021 INDICATIONS AND USAGERYPLAZIM® (plasminogen, human-tvmh) is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). (1) DOSAGE AND ADMINISTRATIONFor intravenous use after reconstitution only. The recommended dosage of RYPLAZIM is 6.6 mg/kg body weight given every 2 to 4 days. (2.1) DOSAGE FORMS AND STRENGTHSRYPLAZIM is available in a single-dose 50-mL vial containing 68.8 mg of plasminogen as a lyophilized powder for reconstitution with 12.5 mL of Sterile Water for Injection, USP (SWFI). After reconstitution, each vial will contain 5.5 mg/mL of plasminogen. (3) CONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most frequent (incidence ≥ 10%) adverse reactions in clinical trials were abdominal pain, bloating, nausea, fatigue, extremity pain, hemorrhage, constipation, dry mouth, headache, dizziness, arthralgia, and back pain. (6) To report SUSPECTED ADVERSE REACTIONS, contact Prometic at +1(855)-353-7466 and US_Medicalinfo@kedrion.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 6/2023 |
RYPLAZIM® (plasminogen, human-tvmh) is plasma-derived human plasminogen indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).
For intravenous use after reconstitution only.
Dose Determination
The recommended dosage of RYPLAZIM is 6.6 mg/kg body weight administered intravenously every 2 to 4 days (Q2D to Q4D).
Calculate the total infusion volume of RYPLAZIM using Formula (1), which is based on a final plasminogen concentration of 5.5 mg/mL. Administer the exact infusion volume determined using Formula (1) to the patient.
Formula (1): | Infusion volume (mL) = body weight (kg) × 1.2 |
May require more than one reconstituted vial of RYPLAZIM to obtain the infusion volume calculated using Formula (1). Round up the estimated number of vials using Formula (2).
Formula (2): | Number of vials = Infusion volume (mL) × 0.08 |
Determination of Dosing Frequency
Prepare RYPLAZIM within 3 hours of administration. Gather the following additional supplies before performing reconstitution and administration:
Reconstitution of RYPLAZIM
Determine the number of RYPLAZIM vials needed using Formula (2) [see Dosage and Administration (2.1)]. Check the expiration date of each vial of RYPLAZIM. Discard any expired vials. Allow RYPLAZIM vials to equilibrate to room temperature before reconstitution (at least 15 minutes if stored at 5 °C). Do not refrigerate after reconstitution.
Work on a clean surface and wash hands before performing the following procedures.
Figure 1
Figure 2
Preparation of RYPLAZIM for Administration
Select an administration syringe of appropriate volume based on the infusion volume calculated using Formula (1) [see Dosage and Administration (2.1)].
Note: A 30-mL syringe can hold up to 2 vials of reconstituted RYPLAZIM and a 60-mL syringe can hold up to 4 vials of reconstituted RYPLAZIM.
Using the selected administration syringe(s) with 18- to 22-gauge needle(s), slowly withdraw the reconstituted RYPLAZIM from each vial to administer the exact infusion volume calculated using Formula (1) [see Dosage and Administration (2.1)].
Do not mix RYPLAZIM with other medications.
For intravenous use only through a syringe disc filter.
Follow the steps below for infusion:
Figure 3
Figure 4
RYPLAZIM is available in a single-dose 50 mL vial containing 68.8 mg of plasminogen as a lyophilized powder for reconstitution with 12.5 mL of sterile water for injection (SWFI). After reconstitution, each vial will contain 5.5 mg/mL of plasminogen in a colorless and clear to slightly opalescent solution.
RYPLAZIM is contraindicated in patients with known hypersensitivity to plasminogen or other components of RYPLAZIM [See Hypersensitivity Reactions (5.4)].
Patients with plasminogen deficiency type 1 may bleed from active mucosal disease-related lesions during RYPLAZIM therapy. Depending on the lesion sites, this may manifest as gastrointestinal (GI) bleeding, hemoptysis, epistaxis, vaginal bleeding, or hematuria.
RYPLAZIM may worsen active bleeding not related to disease lesions. One patient with a recent history of GI bleeding due to gastric ulcers experienced GI bleeding two days after receiving the second dose of RYPLAZIM. The patient received RYPLAZIM through a compassionate use program and the dose was 6.6 mg/kg body weight every 2 days. Endoscopy showed multiple ulcers with one actively bleeding ulcer near the pylorus. Given the mechanism of action of plasminogen in fibrinolysis, it is possible that RYPLAZIM played a role in either prolonging or worsening the active bleeding. RYPLAZIM has not been studied in patients at increased risk for bleeding due to disease or injury.
Prior to initiation of treatment with RYPLAZIM, confirm healing of lesions or wounds suspected as a source of a recent bleeding event. RYPLAZIM may prolong or worsen bleeding in patients with bleeding diatheses or in patients taking anticoagulants and/or antiplatelet drugs and other agents which may interfere with normal coagulation. Monitor patients during and for 4 hours after infusion when administering RYPLAZIM to patients with bleeding diatheses and patients taking anticoagulants, antiplatelet drugs, or other agents which may interfere with normal coagulation. If a patient develops uncontrolled bleeding (defined as any gastrointestinal bleeding or bleeding from any other site that persists longer than 30 minutes), seek emergency care and discontinue RYPLAZIM immediately.
Tissue sloughing at mucosal sites may occur after initiation of treatment with RYPLAZIM as plasminogen activity levels are restored to physiological levels and fibrinolysis occurs. Lesions in the respiratory, gastrointestinal and genitourinary systems may slough following treatment resulting in bleeding or organ obstruction. Patients with tracheobronchial lesions may develop airway obstruction or hemoptysis. Closely monitor patients with either confirmed or suspected airway disease as manifested by cough, wheezing, shortness of breath, or changes in speech (dysphonia). Initiate the treatment with RYPLAZIM in an appropriate clinical setting with personnel trained in airway management and readily-available respiratory support equipment. Monitor at-risk patients in such a settting for a minimum of 4 hours after receiving their first dose of RYPLAZIM.
Patients with gastrointestinal and genitourinary lesions may experience tissue sloughing that causes pain, bleeding, or passage of tissue from affected organ systems. Patients should report persistent abdominal, flank, or pelvic pain to their physicians.
Because RYPLAZIM is derived from human plasma, it carries a risk of transmitting infectious agents. Based on effective donor screening and product manufacturing processes, RYPLAZIM carries a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely low. It is also possible that unknown infectious agents may be present in RYPLAZIM. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for RYPLAZIM [see Description (11)].
Report any infection thought to be possibly transmitted by RYPLAZIM to Prometic at +1(855)-353-7466 and US_Medicalinfo@kedrion.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Hypersensitivity reactions, including anaphylaxis, may occur with RYPLAZIM [see Contraindications (4)]. In case of a hypersensitivity reaction, discontinue RYPLAZIM immediately and treat according to standard medical practice.
Formation of neutralizing antibodies (inhibitors) to plasminogen following the administration of RYPLAZIM has not been reported to date [See Immunogenicity (6.2)]. Monitor patients for the loss of clinical efficacy as manifested by the development of new or recurrent lesions while on RYPLAZIM therapy, and obtain plasminogen activity trough levels to confirm that adequate plasminogen activity levels have been achieved and are being maintained [see Dosage and Administration (2)].
Patients receiving RYPLAZIM may have elevated levels of D-dimer in blood. Intepret D-dimer levels with caution in patients being screened for venous thromboembolism (VTE), as elevated levels may be associated with the physiological activity of RYPLAZIM (fibrinolysis of ligneous lesions) and not indicative of VTE. Consider other tests to screen for VTE in patients receiving RYPLAZIM, as D-dimer levels will lack interpretability.
The most frequent (incidence ≥ 10%) adverse reactions were abdominal pain, bloating, nausea, fatigue, extremity pain, hemorrhage, constipation, dry mouth, headache, dizziness, arthralgia, and back pain.
As clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety data described in this section reflect exposure to RYPLAZIM in two single-arm, open-label clinical trials as well as expanded access and compassionate use programs for a total of 29 patients with plasminogen deficiency type 1 who received at least one dose of RYPLAZIM. Patients were between 11 months and 42 years of age. There were 18 pediatric patients and 11 adult patients. Fifteen patients were female. Twenty-eight patients were Caucasian, and one patient was Asian.
RYPLAZIM Trial 1 enrolled 7 patients (5 female) of whom 2 were pediatric patients (age 13 to 15 years) and 5 were adults. Five patients received two infusions: one 2 mg/kg infusion, and one 6 mg/kg infusion. Two patients received a single 6 mg/kg infusion. There were no adverse reactions in this trial.
RYPLAZIM Trial 2 enrolled 15 patients (11 female) of whom 6 were pediatric patients (age 4 to 16 years) and 9 were adults. Six of the 15 patients participated in RYPLAZIM Trial 1. Treatment duration ranged from 48 to 124 weeks. All patients received RYPLAZIM at a dose of 6.6 mg/kg administered every second, third or fourth day for 48 weeks.
A long-term treatment protocol enrolled 12 patients (8 female) of whom 8 were pediatric patients (age 16 months to 16 years) and 4 were adults. Eight patients in this treatment protocol continued from Trial 2 and 4 patients were from individual expanded access protocols in the US. All 12 patients continue to receive RYPLAZIM at the dose of 6.6 mg/kg every 2 to 4 days.
Fourteen patients (5 female) received RYPLAZIM through expanded access programs. There were 8 pediatric patients (age 11 months to 17 years) and 6 adults. Patients' dosage regimens were adjusted based on clinical response, and the regimens varied between 6.6 mg/kg every 1 to 7 days.
Table 1 shows the most frequent adverse reactions (incidence ≥ 10%) observed in the two trials and in the treatment protocols.
Adverse Reactions | Number of Patients (%)(N = 19) |
---|---|
|
|
Abdominal pain | 3 (16%) |
Gastric dilatation (bloating/feel bloated) | 3 (16%) |
Nausea | 3 (16%) |
Fatigue | 3 (16%) |
Pain in extremity | 3 (16%) |
Hemorrhage | 3 (16%) |
Constipation | 2 (11%) |
Dry mouth | 2 (11%) |
Headache | 2 (11%) |
Dizziness | 2 (11%) |
Arthralgia | 2 (11%) |
Back pain | 2 (11%) |
In RYPLAZIM Trial 2, three patients (20%) developed anti-plasminogen antibodies following RYPLAZIM treatment. Comparison of pharmacokinetic (PK) parameters and /or trough activity levels for those positive samples with the parameters assessed either at baseline or for negative samples suggest these antibodies are not neutralizing antibodies (inhibitors) to plasminogen.
The detection of anti-plasminogen antibodies depends on the sensitivity and specificity of the test methods used. Additionally, the observed incidence of antibody positivity in a test method may be influenced by several factors, including sample handling, timing of sample collection, drug interference, concomitant medication, and the underlying disease. For these reasons, comparison of the incidence of antibodies to RYPLAZIM with the incidence of antibodies to other products may be misleading.
Risk Summary
There are no clinical trials of RYPLAZIM use in pregnant women. No animal reproductive and developmental toxicity studies have been conducted with RYPLAZIM to assess whether it can cause fetal harm when administered to a pregnant woman. In the United States, the background risk of major birth defects is about 3%, and miscarriage occurs in up to 20% of clinically-recognized pregnancies.
Risk Summary
Endogenous plasminogen is excreted in human milk; however, there is no information available on the presence of RYPLAZIM in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for RYPLAZIM and any potential adverse effects on the breastfed infant from RYPLAZIM or from the underlying maternal condition.
The safety and efficacy of RYPLAZIM has been established in pediatric patients. Use of RYPLAZIM is supported by the two clinical trials, and expanded access and compassionate use programs that included 18 pediatric patients age 11 months to 17 years [see Clinical Studies (14), and Adverse Reactions (6)].
The safety and effectiveness of RYPLAZIM have not been established in geriatric patients. Clinical studies of RYPLAZIM for this indication did not include patients age 65 years and over. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
RYPLAZIM is a Glu-plasminogen (> 95% purity) which is the native circulating form of plasminogen in the blood. RYPLAZIM is a sterile, white to off-white, lyophilized preparation of purified, plasma-derived plasminogen (human) to be reconstituted and administered by the intravenous route. Each vial of RYPLAZIM contains 68.8 mg of plasminogen. Following reconstitution with 12.5 mL of sterile water for injection (SWFI), the RYPLAZIM solution contains 5.5 mg/mL plasminogen and the following inactive ingredients: sodium citrate, sodium chloride, glycine, and sucrose. RYPLAZIM contains no preservatives. Biological potency of the plasminogen is determined by a chromogenic assay calibrated with a standard.
All plasma used in the manufacturing of RYPLAZIM is tested using serological assays for hepatitis B virus (HBV) surface antigen and antibodies to human immunodeficiency virus-1/2 (HIV-1/2) and hepatitis C virus (HCV). The plasma is also tested via nucleic acid amplification testing for HBV, HCV, HIV-1, hepatitis A virus (HAV) and human parvovirus B19 virus. Only plasma pools negative for HIV-1, HCV, HBV, and HAV, and containing levels of human parvovirus B19 DNA ≤ 104 IU/mL are used for the manufacture of RYPLAZIM.
The RYPLAZIM manufacturing process encompasses a series of chromatography adsorbents to purify plasminogen and includes multiple steps and controls to ensure that the purified plasminogen is essentially free of known adventitious agents. First, three orthogonal viral removal/inactivation steps are included: affinity chromatography for removal of enveloped and non-enveloped viruses; solvent/detergent treatment for inactivation of enveloped viruses; and 20 nm nanofiltration for removal of both enveloped and non-enveloped viruses. Two independent studies demonstrated effective viral removal/inactivation afforded by these three steps using validated scaled-down models. The overall virus reduction achieved in these studies for enveloped viruses was ≥ 11.8 logs and for non-enveloped viruses was ≥ 9.7 logs (considering both contributing steps), as summarized in Table 2. Second, the plasma used in this process is Human Source Plasma from FDA-approved collection centers; thus, there is minimal risk of contamination that could cause transmissible spongiform encephalopathies. Lastly, the product is tested for microbial and endotoxin levels throughout the process.
Enveloped Viruses | Non EnvelopedViruses | ||||||
---|---|---|---|---|---|---|---|
Process Step | HIV-1 | BVDV | PRV | HAV | PPV | Reo-3 | EMCV |
Affinity chromatography | ≥ 5.22 | ND* | ND* | 3.64 | 2.64 | ND* | 3.55 |
Solvent/Detergent treatment | > 6.09 | > 5.77 | > 6.54 | NA† | NA† | NA† | NA† |
Nanofiltration | > 5.89 | > 6.02 | > 6.51 | > 7.08 | > 7.03 | > 7.08 | ND* |
Total LRV | ≥ 17.2 | ≥ 11.8 | ≥ 13.1 | ≥ 10.7 | ≥ 9.7 | ≥ 7.1 | 3.6 |
Plasminogen deficiency type 1 is characterized by decreased plasminogen levels that causes formation of fibrin-rich, ligneous pseudomembranous lesions on mucous membranes that can impair normal tissue and organ function. Replacemenq t therapy increases the plasma level of plasminogen enabling a temporary correction of the plasminogen deficiency and reduction or resolution of extravascular fibrinous lesions.
The pharmacokinetics of RYPLAZIM were assessed by plasminogen activity (chromogenic assay) in plasma. Plasminogen was measured as both absolute and baseline-adjustedlevels.
In RYPLAZIM Trial 2, pharmacokinetic analyses were conducted in 15 patients (9 adults) who completed at least 12 weeks of RYPLAZIM 6.6 mg/kg administered every second, third or fourth day and had sufficient plasma samples. Full pharmacokinetic profiles of plasminogen were measured over 96 hours after the first and Week 12 infusions, and trough levels of plasminogen were measured at baseline and at Weeks 2, 4, 6, 8, 10, and 12.
Mean absolute plasminogen activity in adult and pediatric patients reached physiological levels (70% to 130%) immediately after the first infusion, were sustained for approximately 24 hours, and remained an absolute 10% above baseline 72 hours after dosing. After 12 weeks, mean absolute plasminogen activity in adult and pediatric patients reached physiological levels (70% to 130%) immediately after dosing, were sustained for approximately 24 hours, and continued to maintain an absolute 10% above baseline 96 hours after dosing.
Although some inter-patient variability was observed, PK parameters for baseline-adjusted plasminogen activity levels were generally similar between adult and pediatric patients.
PK Parameter | First Dose Adult (N=9) | Week 12 Adult (N=9) | First Dose Pediatric (N=6) | Week 12 Pediatric (N=6) | First Dose Total (N=15) | Week 12 Total (N=15) |
---|---|---|---|---|---|---|
AUCLast = area under the time-concentration curve, from time 0 to the last measured time point; AUCInf = extrapolated area under the time-concentration curve, from time 0 to infinity; CL = clearance; Cmax = peak concentration; MRTLast = mean residence time from time 0 to the last measured time point; Vss = steady-state volume of distribution; T1/2 = half-life | ||||||
|
||||||
AUCLast (hr*%) | 2860.9 (700.7) | 4665.6 (762.1) | 3367.6 (852.8) | 4641.6 (1393.4) | 3063.6 (778.7) | 4656.0 (1012.7) |
AUCInf (hr*%) | 3317.3 (915.7) | 5676.0 (1186.6) | 4038.5 (1104.2) | 5815.5 (1863.5) | 3605.8 (1023.9) | 5731.8 (1431.7) |
CL (mL/h/kg) | 1.5 (0.5) | 0.9 (0.2) | 1.3 (0.4) | 0.9 (0.3) | 1.4 (0.5) | 0.9 (0.3) |
Cmax (%) | 90.9 (17.5) | 127.4 (17.4) | 102.0 (31.1) | 120.3 (31.6) | 95.3 (23.5) | 124.6 (23.3) |
MRTLast (hr) | 29.7 (3.7) | 33.0 (1.6) | 31.8 (2.0) | 34.2 (1.5) | 30.6 (3.2) | 33.5 (1.6) |
Vss (mL/kg) | 62.8 (11.2) | 47.2 (5.6) | 64.1 (12.9) | 52.5 (15.2) | 63.3 (11.4) | 49.3 (10.4) |
T1/2 (hr) | 32.4 (13.1) | 38.5 (7.1) | 36.3 (10.0) | 40.3 (5.0) | 34.0 (11.7) | 39.2 (6.2) |
Study Population | Baseline | Week 2 | Week 4 | Week 6 | Week 8 | Week 10 | Week 12 |
---|---|---|---|---|---|---|---|
Plasminogen activity levels measured with a chromogenic assay. Normal range: 70%-130%, as determined by the laboratory. Individual plasminogen activity values reported as < 5% were set at 5% for mean calculation. There was no Week 2 plasminogen activity trough value for one adult patient; however, an unscheduled Week 3 value was obtained and used for mean calculation. Baseline value corresponds to endogenous plasminogen level. |
|||||||
Adult (N = 9) | 20.3 (13.7) | 44.7 (18.6) | 50.8 (17.1) | 55.4 (12.0) | 50.3 (19.5) | 51.1 (15.5) | 51.7 (12.3) |
Pediatric (N = 6) | 22.3 (5.1) | 47.7 (7.4) | 46.2 (10.5) | 47.8 (9.8) | 45.2 (14.8) | 48.8 (6.4) | 50.0 (12 6) |
Combined (N = 15) | 21.1 (10.8) | 45.9 (14.8) | 48.9 (14.6) | 52.4 (11.5) | 48.3 (17.4) | 50.2 (12.4) | 51.0 (12.0) |
The efficacy of RYPLAZIM in pediatric and adult patients with plasminogen deficiency type 1 was evaluated in a single-arm, open-label clinical trial (RYPLAZIM Trial 2). A total of 15 patients with plasminogen deficiency type 1 were enrolled. All patients had a baseline plasminogen activity level between <5% and 45% of normal, and biallelic mutations in the plasminogen (PLG) gene. The age range of these patients was 4 to 42 years, including 6 pediatric patients age 4 to 16 years, and 9 adults. Eleven patients were female. All patients were White. All patients received RYPLAZIM at a dose of 6.6 mg/kg administered every 2 to 4 days for 48 weeks to achieve at least an increase of individual trough plasminogen activity by an absolute 10% above baseline and to treat the clinical manifestations of the disease.
Efficacy was established on the basis of overall rate of clinical success at 48 weeks. Overall rate of clinical success is defined as 50% of patients with visible or other measurable non-visible lesions achieving at least 50% improvement in lesion number/size, or functionality impact from baseline. Spirometry was the only test of organ function used and one patient had abnormal spirometry at baseline. This patient had a history of ligneous airway disease with a severe obstructive ventilatory defect (FEV1: 46.7% of predicted normal) at baseline prior to treatment that corrected to normal (FEV1: 89.3% of predicted normal) after 12 weeks of treatment. All patients with any lesion at baseline had at least 50% improvement in the number/size of their lesions.
External Lesions: Twenty-five of the 32 (78%) external lesions [with sites mainly located in the eyes (ligneous conjunctivitis), nose, gums (ligneous gingivitis), ligneous lesions of the hands and feet] were resolved by the end of Week 48. There were no recurrent or new external lesions in any patient through Week 48.
RYPLAZIM is supplied in a single-dose vial [NDC 70573-099-01] containing 68.8 mg of plasminogen (human) (5.5 mg/mL after reconstitution with 12.5 mL of SWFI), one vial per carton [NDC 70573-099-02]. The treating physician will provide reconstitution and administration supplies. RYPLAZIM contains no preservatives.
Manufactured by:
Prometic Bioproduction, Inc
531 Blvd. des Prairies, Building 15
Laval, Quebec, Canada, H7V1B7
Manufactured for:
Prometic Biotherapeutics, Inc
Parker Plaza, 400 Kelby Street, Suite 1104
Fort Lee, New Jersey 07024
U.S. License number 2065
RYPLAZIM®
plasminogen, human-tvmh
The following summarizes important information that you should read carefully before using RYPLAZIM (pronounced ri plaz' im). This does not replace talking with your healthcare provider, and it does not include all of the important information about RYPLAZIM. If you have any questions after reading this information, then ask your healthcare provider.
What is RYPLAZIM?
RYPLAZIM is a medicine containing human plasminogen and is used to increase the blood levels of plasminogen in people with plasminogen deficiency type 1 (hypoplasminogenemia). It is injected into a vein.
Who should not use RYPLAZIM?
Do not take RYPLAZIM if you have had a severe reaction to RYPLAZIM or another product containing plasminogen.
What should I tell my healthcare provider before using RYPLAZIM?
Before taking RYPLAZIM, tell your healthcare provider if you:
How do I take RYPLAZIM?
What are the possible or reasonably likely side effects of RYPLAZIM?
You may report side effects to +1(855)-353-7466 and US_Medicalinfo@kedrion.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
How do I store RYPLAZIM?
Do not use RYPLAZIM for a condition other than that prescribed by your healthcare provider.
Do not share RYPLAZIM with other people, even if they have the same symptoms that you have.
For intravenous use after reconstitution only
Do not attempt an intravenous infusion on yourself unless you or your caregiver has been trained by a healthcare provider. Always follow the specific instructions that your healthcare provider has given you. The steps listed below are general guidelines for using RYPLAZIM. If you are unsure about any of the steps, contact your healthcare provider before using.
Fig. A
Fig. B
Infusing RYPLAZIM
Fig. C
Fig. D
Manufactured by:
Prometic Bioproduction Inc
531 Blvd. des Prairies,
Laval, Quebec, Canada, H7V1B7
Manufactured for:
Prometic Biotherapeutics, Inc
Parker Plaza, 400 Kelby Street, Suite 1104
Fort Lee, New Jersey 07024
U.S. License number 2065
RYPLAZIM
plasminogen injection, powder, lyophilized, for solution |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
Labeler - Prometic Biotherapeutics, Inc. (961577439) |